Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …

Background. Oral antineoplastic therapies not only improve survival but also reduce the
burden of care for patients. Yet patients and clinicians face new challenges in managing …

Deregulated activity of BCR-ABL1, a nonreceptor tyrosine kinase encoded by the fusion
gene resulting from the t (9; 22)(q34; q11) chromosomal translocation, is thought to be the …

Purpose: Although patients with cancer overwhelming prefer oral to intravenous
chemotherapy, little is known about adherence to oral agents. We aimed to identify the rates …

Background: Chemotherapy-induced nausea and vomiting (CINV) continue to be a
distressing problem still reported by cancer patients, with negative consequences on quality …

Optimal adherence to CML therapy is of key importance to maximize treatment effectiveness.
Two clinical studies (ADAGIO and Hammersmith) have proven a clear correlation between …

Individuals diagnosed with hematologic malignancies experience significant unmet
psychological, physical, informational, financial, and spiritual needs. The goal of the current …

Background Medication non-adherence is associated with poor health outcomes and
increased health care costs. Depending on definitions, reported non-adherence rates in …

A rapidly growing number of oral anticancer agents has become available in oncology and
hematology. Though these introductions have several benefits, medication adherence is an …

Medication adherence is directly associated with health outcomes. Adherence has been
reviewed extensively; however, most studies provide a narrow scope of the problem …